A Phase 3 interventional study of Levosimendan in Amyotrophic Lateral Sclerosis, sponsored by Orion Corporation, Orion Pharma. Terminated at 79 sites in 14 countries. Open to participants aged 18 Years to 120 Years. Per ClinicalTrials.gov, last updated 2023-03-09.
Sponsored by Orion Corporation, Orion Pharma · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 440 studies in Amyotrophic Lateral Sclerosis with a site in United States — 98 open to participants now, 129 under way, 11 of them phase 3. Amyotrophic Lateral Sclerosis · United States.
Among the 440 studies in Amyotrophic Lateral Sclerosis with a site in United States, this one is the 39th largest by enrollment of the 307 interventional ones that give a count, is one of 20 that started in 2019, is one of 30 in phase 3, and was the 238th registered.
981 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 280 are open to participants now.
Browse Amyotrophic Lateral Sclerosis studies →98 of the 440 studies in Amyotrophic Lateral Sclerosis with a site in United States are open now. Recruiting first, the newest first:
Johns Hopkins University · Sites in United States
Ages 18–80
Cognixion · Sites in United States
Ages 18+
Johns Hopkins University · Sites in United States
Ages 18+ · Healthy volunteers
Neuralink Corp · Sites in United States
Ages 18+
Biogen · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 194 Amyotrophic Lateral Sclerosis studies recruiting now, 119 (61%) set no upper age limit and 23 (12%) stop at 75 or younger; 15 take children under 18; 56 take healthy volunteers.
This study: 18 Years to 120 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
440 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 89 · Phase 2 139 · Phase 3 48 · Phase 4 1
First in 1982; this study’s year is marked. 20 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 227 is above the median of 38 across 664 interventional studies indexed under Amyotrophic Lateral Sclerosis.
Median enrollment 33 across the 307 interventional studies, 100 across the 121 observational. Of the 277 that completed or were terminated, 102 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
163 of 440 have an industry lead sponsor. The 10 most frequent:
Orion Corporation, Orion Pharma is the lead sponsor of 101 studies on the registry; 3 are open to participants now.
Orion Corporation, Orion Pharma has 3 studies filed under Amyotrophic Lateral Sclerosis — fewer than ten, so there is no comparison to draw.
41 of the studies in Amyotrophic Lateral Sclerosis with a site in United States that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07161999Phase 3Coya TherapeuticsStudy of COYA 302 for the Treatment of ALS | 2027-04 |
| NCT04057898Phase 3MediciNovaEvaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS | 2027-04 |
| NCT04297683Phase 3Merit E. Cudkowicz, MDHEALEY ALS Platform Trial - Master Protocol | 2027-07 |
| NCT07410806Phase 3Merit E. Cudkowicz, MDHEALEY ALS Platform Trial - Regimen I NUZ-001 | 2027-07-01 |
| NCT04220190Phase 3Rapa Therapeutics LLCRAPA-501 Therapy for ALS | 2027-07-01 |
Add all 41 to your calendar (.ics) → With an account.
Among the 440 studies in Amyotrophic Lateral Sclerosis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study provides an opportunity for subjects in the REFALS (3119002; NCT03505021) study to continue treatment with oral levosimendan. The study will also provide more information about long-term safety and effectiveness of oral levosimendan in patients with ALS.
This is an open-label study, so that all eligible subjects that complete the double-blind REFALS study (48-weeks of treatment) will have the opportunity to receive oral levosimendan treatment. The primary objective, in addition to continuing treatment for subjects enrolled in the REFALS study, is to evaluate long-term safety of oral levosimendan in ALS patients. Another important objective is to explore long-term effectiveness of oral levosimendan in the treatment of patients with ALS.
This study is open only to patients taking part in the REFALS study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Oral Levosimendan; Levosimendan 1mg capsules for oral administration, once to twice a day, continued as long as clinically beneficial. The total study duration is up to 3 years.
Drug: Levosimendan
Levosimendan 1 mg capsule for oral administration
Also known as: ODM-109
Adverse Events Recording
Adverse Events as subject counts and proportions (%) of subject per Adverse Event
Time frame: From signing informed consent until 14-25 days after the last study treatment for all patients, an average of 23.5 weeks.
Pulse/Heart Rate Assessment
Actual values and changes from baseline in supine pre-dose pulse/heart rate were summarised using descriptive statistics .
Time frame: Change in pulse and heart rate(from ECG recording) from Baseline, week 2, week 4, week 6 (pulse rate only), Month 3, Month 6, end of study (subject's last visit, 2-48 weeks after study entry)
12-lead Electrocardiogram Assessments
Summarisation of any abnormal 12-lead ECG findings using descriptive statistics.
Time frame: Baseline, week 2, week 4, month 3, month 6, end-of-study(subject's last visit, 2-48 weeks after study entry)
Disease Progression
Count of study withdrawals due to disease progression
Time frame: From Baseline through study completion(subject's last visit, 2-48 weeks after study entry)
Supine Slow Vital Capacity (SVC)
Change from baseline in supine and sitting SVC (all devices) through to the end of the study, expressed as a % of predicted normal
Time frame: The change from Baseline, week 2, week 4, month 3, month 6, end-of-study (subject's last visit, 2-48 weeks after study entry)
Revised ALS Functional Rating Scale (ALSFRS-R)
ALSFRS-R scale contains 3 parameters related to respiratory function: Severity of dyspnea, occurrence of orthopnea (shortness of breath when in supine position i.e. lying flat), and the use of mechanical ventilation for respiratory in sufficiency. These 3 parameters are combined to create the respiratory domain with a score of 0-12(where 12 is normal function). Although individual items and patients vary, ALSFRS-R typically declines at a relatively constant rate over time. Plotted over time the slope of the line obtained indicates the speed of progression and thus an effective treatment might be expected ro reduce the slope of decline.
Time frame: Change from Baseline in respiratory function of ALSFRS-R at study completion (subject's last visit, 2-48 weeks after study entry)
Need for Respiratory Support Device
Time to respiratory device support (non invasive) or death
Time frame: Time to event at study completion (subject's last visit, 2-48 weeks after study entry)
Borg Category Ratio 10 Scale (CR 10)
Patients rated their perception of the severity of their dyspnea using the Borg Category Ration 10 scale (CR 10). The scale ranges from 0(no dysponea) to 10 (maximal dyspnea). each category is numbered and most but not all have verbal cues. At each assessment the patient scored the category they felt best described their symptoms. The analysis measured change from baseline to the end of the study in both a supine and sitting position where a negative score indicates improvement and a positive score reflects worsening.
Time frame: Baseline through study completion (week 2, week 4, month 3, month 6, end of study (subject's last visit, 2-48 weeks after study entry)
Number of Subjects Requiring Health and Home Care Resource Use
The number of study subjects requiring Health and home care resource use was aggregated over the course of the study for each subject and summarised using descriptive statistics.
Time frame: Baseline through study completion (2- 48 weeks after study entry)
Subject's Status for Tracheostomy and Survival
Number of patients with the need for tracheostomy or who died whilst on treatment from baseline to the end of the study was summarised using descriptive statistics.
Time frame: Baseline to end of study (average 2-48 weeks after study entry
Health Care Service Use During the Study(Stays in Hospital)
The number of night stays in hospital were recorded throughout the study using a diary given to the study subjects
Time frame: From baseline to the end of the study(2-48 weeks after study entry)
Health Care Service Use During the Study(Visits to the Emergency Room)
The number of visits to the emergency room were recorded throughout the study using a diary given to the study subjects
Time frame: From baseline to the end of the study(2-48 weeks after study entry)
Health Care Service Use During the Study (Days Spent in an Institutional Facility)
The number of days spent in an institutional facility were recorded throughout the study using a diary given to the study subjects
Time frame: From baseline to the end of the study(2-48 weeks after study entry)
Patients with amyotrophic lateral sclerosis (ALS) who completed 48 weeks of treatment in the REFALS study (NCT03505021) were recruited
| Milestone | Levosimendan |
|---|---|
| Started | 227 |
| Completed | 0 |
| Not completed | 227 |
| Withdrew: Protocol violation | 1 |
| Withdrew: Lost to follow-up | 2 |
| Withdrew: Withdrawal by subject | 2 |
| Withdrew: Reason not known | 2 |
| Withdrew: Personal reason | 14 |
| Withdrew: Disease progression | 30 |
| Withdrew: Adverse event | 12 |
| Withdrew: Sponsor terminated study | 164 |
Adverse Events as subject counts and proportions (%) of subject per Adverse Event
| Participants | Levosimendan |
|---|---|
| Adverse Events Recording | 161 |
Actual values and changes from baseline in supine pre-dose pulse/heart rate were summarised using descriptive statistics .
| beats per minute (bpm) | Levosimendan |
|---|---|
| Change in pulse rate at week 2 | 7.0 ± 8.8 |
| Change in pulse rate at 4 weeks | 10.0 ± 10.4 |
| Change in pulse rate at week 6 | 8.5 ± 12.0 |
| chnage in pulse rate at Month 3 | 10.4 ± 10.6 |
| Change in pulse rate at month 6 | 12.8 ± 10.6 |
| Change in pulse rate at end-of-study | 3.5 ± 12.6 |
| Change in Heart rate at week 2 | 9.1 ± 10.1 |
| Change in Heart rate at week 4 | 12.8 ± 9.4 |
| Change in heart rate at Month 3 | 12.6 ± 9.3 |
| Change in heart rate at month 6 | 15.0 ± 9.9 |
| Change in heart rate at end-of-study | 5.3 ± 10.9 |
| Baseline supine pulse rate | 75.8 ± 12.5 |
| Baseline supine heart rate | 73.5 ± 12.0 |
Summarisation of any abnormal 12-lead ECG findings using descriptive statistics.
| Participants | Levosimendan |
|---|---|
| Baseline abnormal ECG | 69 |
| Week 2 abnormal ECG | 56 |
| Week 4 abnormal ECG | 43 |
| Month 3 abnormal ECG | 27 |
| Month 6 abnormal ECG | 11 |
| End-of study abnormal ECG | 36 |
Count of study withdrawals due to disease progression
| Participants | Levosimendan |
|---|---|
| Total withdrawal due to sponsor terminating the study | 164 |
| Number of withdrawals due to disease progression | 30 |
Change from baseline in supine and sitting SVC (all devices) through to the end of the study, expressed as a % of predicted normal
| % of predicted normal | Levosimendan |
|---|---|
| Change from baseline in supine SVC at week 2 | 1.5 ± 7.2 |
| Change from baseline in supine SVC at week 4 | 0.8 ± 10.2 |
| Change from baseline in supine SVC at month 3 | -3.5 ± 10.4 |
| Change from baseline in supine SVC at month 6 | -5.3 ± 13.2 |
| Change from baseline in supine SVC at the end of the study | -5.6 ± 17.4 |
| Change from baseline in sitting SVC at week 2 | 1.4 ± 6.6 |
| Change from baseline in sitting SVC at week 4 | 2.1 ± 9.8 |
| Change from baseline in sitting SVC month 3 | -1.9 ± 11.9 |
| Change from baseline in sitting SVC month 6 | -6.1 ± 12.4 |
| Change from baseline in sitting SVC at the end of the study | -7.3 ± 12.1 |
| Baseline Supine SVC (% predicted normal | 54.4 ± 21.6 |
| Baseline Sitting SVC (% predicted normal) | 61.4 ± 19.4 |
ALSFRS-R scale contains 3 parameters related to respiratory function: Severity of dyspnea, occurrence of orthopnea (shortness of breath when in supine position i.e. lying flat), and the use of mechanical ventilation for respiratory in sufficiency. These 3 parameters are combined to create the respiratory domain with a score of 0-12(where 12 is normal function). Although individual items and patients vary, ALSFRS-R typically declines at a relatively constant rate over time. Plotted over time the slope of the line obtained indicates the speed of progression and thus an effective treatment might be expected ro reduce the slope of decline.
| Score on a scale | Levosimendan |
|---|---|
| Change from baseline in respiratory function ALSFR-S at end of study | -1.2 ± 2.3 |
| Baseline respiratory ALSFRS-R | 9.4 ± 3.0 |
Time to respiratory device support (non invasive) or death
| days | Levosimendan |
|---|---|
| Need for Respiratory Support Device | 259.5 ± 10.46 |
Patients rated their perception of the severity of their dyspnea using the Borg Category Ration 10 scale (CR 10). The scale ranges from 0(no dysponea) to 10 (maximal dyspnea). each category is numbered and most but not all have verbal cues. At each assessment the patient scored the category they felt best described their symptoms. The analysis measured change from baseline to the end of the study in both a supine and sitting position where a negative score indicates improvement and a positive score reflects worsening.
| units on a scale | Levosimendan |
|---|---|
| Baseline in Borg score Supine position | 2.52 ± 2.62 |
| Change from baseline in Borg score supine at week 2 | 0.15 ± 2.16 |
| chenge from baseline in Borg score week 4 | 0.40 ± 2.21 |
| Change from baseline in Borg score supine at month 3 | 0.54 ± 2.05 |
| Change from baseline in Borg score supine at month 6 | 1.61 ± 2.07 |
| Change from baseline in Borg score supine at end of study | 1.58 ± 2.78 |
| Baseline Borg score sitting | 2.19 ± 2.33 |
| Change from baseline in Borg score sitting at week 2 | 0.01 ± 1.71 |
| Change from baseline in Borg score sitting at week 4 | 0.34 ± 1.94 |
| Change from baseline in Borg score sitting at month 3 | 0.61 ± 2.08 |
| Change from baseline in Borg score sitting month 6 | 1.2 ± 1.87 |
| Change from baseline in Borg score sitting at end of study | 1.07 ± 2.54 |
The number of study subjects requiring Health and home care resource use was aggregated over the course of the study for each subject and summarised using descriptive statistics.
| Participants | Levosimendan |
|---|---|
| Number of Subjects Requiring Health and Home Care Resource Use | 95 |
Number of patients with the need for tracheostomy or who died whilst on treatment from baseline to the end of the study was summarised using descriptive statistics.
| Participants | Levosimendan |
|---|---|
| Number of participants who died from baseline to end of the study treatment | 5 |
| Number of participants requiring tracheostomy from baseline to the end of the study treatment | 0 |
The number of night stays in hospital were recorded throughout the study using a diary given to the study subjects
| Nights | Levosimendan |
|---|---|
| Health Care Service Use During the Study(Stays in Hospital) | 0.7 ± 2.7 |
The number of visits to the emergency room were recorded throughout the study using a diary given to the study subjects
| visits | Levosimendan |
|---|---|
| Health Care Service Use During the Study(Visits to the Emergency Room) | 0.1 ± 0.4 |
The number of days spent in an institutional facility were recorded throughout the study using a diary given to the study subjects
| days | Levosimendan |
|---|---|
| Health Care Service Use During the Study (Days Spent in an Institutional Facility) | 4.7 ± 28.2 |
Collected over From signing informed consent until 14-25 days after the last study treatment administration, an average of 23.5 weeks.. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Levosimendan | 19/227 (8.4%) | 44/227 (19.4%) | 215/227 (94.7%) |
| Event | Levosimendan |
|---|---|
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 11/227 |
| PneumoniaInfections and infestations | 4/227 |
| DysponeaRespiratory, thoracic and mediastinal disorders | 2/227 |
| Urinary Tract InfectionInfections and infestations | 2/227 |
| Stoma Site PainInjury, poisoning and procedural complications | 2/227 |
| FallInjury, poisoning and procedural complications | 2/227 |
| Back PainMetabolism and nutrition disorders | 2/227 |
| Respiratory distressRespiratory, thoracic and mediastinal disorders | 1/227 |
| ChokingRespiratory, thoracic and mediastinal disorders | 1/227 |
| Pulmonary EmbolismRespiratory, thoracic and mediastinal disorders | 1/227 |
| Event | Levosimendan |
|---|---|
| FallInjury, poisoning and procedural complications | 25/227 |
| HeadacheNervous system disorders | 20/227 |
| TachycardiaCardiac disorders | 18/227 |
| DysponeaRespiratory, thoracic and mediastinal disorders | 14/227 |
| Respiratory FailureRespiratory, thoracic and mediastinal disorders | 13/227 |
| Heart Rate IncreasedInvestigations | 12/227 |
| DysphagiaGastrointestinal disorders | 11/227 |
| ConstipationGastrointestinal disorders | 10/227 |
| NasopharyngitisInfections and infestations | 10/227 |
| DiarrhoeaGastrointestinal disorders | 9/227 |
Intention-to-Treat (ITT) including all randomised subjects was used for the primary evaluation.
| Age, Categorical(Participants) | Levosimendan |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 160 |
| >=65 years | 67 |
| Sex: Female, Male(Participants) | Levosimendan |
|---|---|
| Female | 85 |
| Male | 142 |
| Ethnicity (NIH/OMB)(Participants) | Levosimendan |
|---|---|
| Hispanic or Latino | 3 |
| Not Hispanic or Latino | 224 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Levosimendan |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 218 |
| More than one race | 0 |
| Unknown or Not Reported | 9 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jun 2019 to primary completion in Nov 2020, 16 months.
Results were first posted in Mar 2023, 2 years 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Simendan
Amyotrophic Lateral Sclerosis →
Orion Corporation, Orion Pharma →